EFAXIL XL

देश: आयरलैंड

भाषा: अंग्रेज़ी

स्रोत: HPRA (Health Products Regulatory Authority)

30-04-2024

इस उत्पाद के लिए कुछ दस्तावेज़ वर्तमान में उपलब्ध नहीं हैं, आप हमारी ग्राहक सेवा को अनुरोध भेज सकते हैं और जैसे ही हम उन्हें प्राप्त करने में सक्षम होंगे, हम आपको सूचित करेंगे।
अनुरोध भेजा।

सक्रिय संघटक:

VENLAFAXINE HYDROCHLORIDE

थमां उपलब्ध:

Pinewood Laboratories Ltd,

डोज़:

150 Milligram

फार्मास्यूटिकल फॉर्म:

Prolonged Release Capsules

प्राधिकरण की तारीख:

2008-12-02

उत्पाद विशेषताएं

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Efaxil XL 150mg Prolonged-release Capsules
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each prolonged-release capsule contains 150mg of venlafaxine as venlafaxine hydrochloride.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Prolonged-release Capsule.
Scarlet opaque/scarlet opaque, size 00 hard gelatin capsules containing three white round, biconvex film-coated tablets.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Treatment of major depressive episodes.
For prevention of recurrence of major depressive episodes.
Treatment of social anxiety disorder.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
_MAJOR DEPRESSIVE EPISODES_
The recommended starting dose for prolonged-release venlafaxine is 75 mg given once daily. Patients not responding
to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of 375 mg/day. Dosage increases
can be made at intervals of 2 weeks or more. If clinically warranted due to symptom severity, dose increases can be
made at more frequent intervals, but not less than 4 days.Because of the risk of dose-related adverse effects, dose
increments should be made only after a clinical evaluation (see section 4.4). The lowest effective dose should be
maintained.
Patients should be treated for sufficient period of time, usually several months or longer. Treatment should be
reassessed regularly on a case-by-case basis. Longer-term treatment may also be appropriate for prevention of
recurrence of major depressive episodes (MDE). In most of the cases, the recommended dose in prevention of
recurrence of MDE is the same as the one used during the current episode.
Antidepressive medicinal products should continue for at least six months following remission.
_SOCIA

पूरा दस्तावेज़ पढ़ें

EFAXIL XL

सक्रिय संघटक:

थमां उपलब्ध:

डोज़:

फार्मास्यूटिकल फॉर्म:

प्राधिकरण की तारीख:

उत्पाद विशेषताएं

इसी तरह के उत्पादों

सक्रिय संघटक

निर्माता या प्राधिकरण धारक

इस उत्पाद से संबंधित अलर्ट देखें

चेतावनियाँ

दस्तावेज़ इतिहास देखें

दस्तावेज़ इतिहास